U.S. Labeling, Artwork & Compliance Review
Ensuring your products meet FDA labeling expectations—before they enter the U.S. market.
Accurate labeling is one of the most visible and heavily scrutinized components of FDA compliance. Whether you manufacture prescription drugs, OTC products, or dietary supplements, even small mistakes in claims, formatting, NDC placement, or required statements can lead to misbranding, import delays, warning letters, or listing inconsistencies.
Axentra provides a precise and risk-focused labeling review service that verifies your artwork, label content, and package design against FDA requirements, 21 CFR rules, and SPL/NDC alignment standards. This service is designed to be fast, reliable, and extremely valuable for manufacturers preparing products for the U.S. market.
FDA Labeling Validation for Drugs, OTC Products & Supplements
Axentra reviews your full label set—including bottle/carton labels, inserts, and artwork—to ensure complete compliance with 21 CFR labeling requirements. We verify that all mandatory statements, warnings, storage conditions, dosage instructions, active ingredient declarations, and FDA-standard formatting elements are present, accurate, and positioned correctly.
Our review covers prescription (Rx), over-the-counter (OTC), and dietary supplement categories, with specific attention to drug facts formatting, supplement facts panel requirements, and FDA-mandated type hierarchy.
NDC Formatting, SPL Alignment & Regulatory Consistency Checks
Incorrect or inconsistently used NDC numbers are one of the most common causes of listing errors, import issues, and FDA database discrepancies. Axentra verifies NDC format, placement, hyphenation rules, and carton-to-bottle alignment, ensuring full consistency between your labeling, SPL submission, and drug listing records.
We also check that your label text is consistent with the structured elements of your SPL (Structured Product Labeling) file, helping prevent misbranding, listing rejections, and labeling/registration mismatches.
Artwork Layout Review, Claims Assessment & 21 CFR Compliance Scan
Beyond text accuracy, the visual layout of your artwork must follow strict rules for legibility, hierarchy, and prominence. Axentra performs a layout-level pre-check to ensure type size, placement, color contrast, branding elements, and panel organization meet FDA and 21 CFR expectations.
We also review product claims—“drug,” “supplement,” “cosmetic,” structure/function, and therapeutic claims—to identify high-risk language that could trigger FDA scrutiny or classification issues. Our assessment ensures your labeling is not only compliant but also commercially safe for the U.S. market.